A non-randomised Phase III study to evaluate the effectiveness of Deflazacort in boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.
Phase 3
Recruiting
- Conditions
- Duchenne muscular dystrophyMusculoskeletal - Other muscular and skeletal disorders
- Registration Number
- ACTRN12605000077662
- Lead Sponsor
- The Children's Hospital at Westmead
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Duchenne muscular dystrophy, walking independently, failed Prednisone.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in muscle strength[Measured prior to commencement on deflazacort, then 1, 3, 6, 9 and 12 months after starting the treatment.]
- Secondary Outcome Measures
Name Time Method Minimum side effects (weight gain, behavioural changes).[]